Genshin Impact has officially revealed the details of all 4-star characters and weapons that will be featured during Phase 1 ...
Huntsman Cancer Institute at the University of Utah stands at the forefront of innovative cancer research and treatment. Phase 1 clinical trials are key to finding better ways to treat cancer safely ...
SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing ...
-- Favorable Safety Profile: PAS-004 has been well-tolerated with all treatment-related adverse events Grade 1 or 2, no ocular or cardio toxicity, and limited rash, nausea, diarrhea, and vomiting to ...
A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract ...
Tb-161 antitumor activity driven by the dual emission of beta particles and Auger electrons ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback